D M Wilcock

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2
    Donna M Wilcock
    Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurosci 28:1537-45. 2008
  2. ncbi Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials
    Donna M Wilcock
    Duke University Medical Center, Department of Medicine Division of Neurology, Durham, NC 27710, USA
    J Alzheimers Dis 15:555-69. 2008
  3. ncbi Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice
    Donna M Wilcock
    Duke University Medical Center, Division of Neurology, Research Dr, Durham, NC 27710, USA
    CNS Neurol Disord Drug Targets 8:50-64. 2009
  4. ncbi Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease
    D M Wilcock
    Duke University Medical Center, Division of Neurology, Bryan Research Building, Box 2900, Research Drive, Durham, NC 27710, USA
    Neuroscience 159:1055-69. 2009
  5. ncbi Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease
    Donna M Wilcock
    Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurosci 29:7957-65. 2009
  6. ncbi Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease
    H N Dawson
    Division of Neurology, Duke University, Durham, NC 27710, USA
    Neuroscience 169:516-31. 2010
  7. ncbi Assessing activation states in microglia
    Carol A Colton
    Duke University Medical Center, Durham, NC 27710, USA
    CNS Neurol Disord Drug Targets 9:174-91. 2010
  8. ncbi The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP
    Carol A Colton
    Division of Neurology, Duke University Medical Center, Durham, NC 27710, USA
    J Alzheimers Dis 15:571-87. 2008
  9. ncbi The usefulness and challenges of transgenic mouse models in the study of Alzheimer's disease
    Donna M Wilcock
    Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA
    CNS Neurol Disord Drug Targets 9:386-94. 2010

Research Grants

  1. Dysregulation of the neurovascular unit in Alzheimer's Disease.
    Donna Wilcock; Fiscal Year: 2007

Detail Information

Publications9

  1. ncbi Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2
    Donna M Wilcock
    Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurosci 28:1537-45. 2008
    ..These data show that removal of NOS2 from an APP transgenic mouse results in development of a much greater spectrum of AD-like pathology and behavioral impairments...
  2. ncbi Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials
    Donna M Wilcock
    Duke University Medical Center, Department of Medicine Division of Neurology, Durham, NC 27710, USA
    J Alzheimers Dis 15:555-69. 2008
    ..Reports from the active immunization clinical trial indicated that, similarly to effects observed in mouse studies, amyloid levels in brain were reduced...
  3. ncbi Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice
    Donna M Wilcock
    Duke University Medical Center, Division of Neurology, Research Dr, Durham, NC 27710, USA
    CNS Neurol Disord Drug Targets 8:50-64. 2009
    ..Understanding the type of damage to the neurovascular unit caused by CAA in AD and the underlying cause of microhemorrhage after immunotherapy is essential to the success of therapeutic vaccines as a treatment for AD...
  4. ncbi Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease
    D M Wilcock
    Duke University Medical Center, Division of Neurology, Bryan Research Building, Box 2900, Research Drive, Durham, NC 27710, USA
    Neuroscience 159:1055-69. 2009
    ..Together, these data suggest that damage to the neurovascular unit may be a factor in the pathogenesis of Alzheimer's disease...
  5. ncbi Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease
    Donna M Wilcock
    Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurosci 29:7957-65. 2009
    ..Nevertheless, by providing evidence that reducing amyloid pathology also reduces nonmutant tau pathology and blocks neuron loss, these data support the development of amyloid-lowering therapies for disease-modifying treatment of AD...
  6. ncbi Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease
    H N Dawson
    Division of Neurology, Duke University, Durham, NC 27710, USA
    Neuroscience 169:516-31. 2010
    ..1993; Terry, 1996; Stokin et al., 2005), and our current data suggests that loss of tau function may lead to neurodegeneration...
  7. ncbi Assessing activation states in microglia
    Carol A Colton
    Duke University Medical Center, Durham, NC 27710, USA
    CNS Neurol Disord Drug Targets 9:174-91. 2010
    ..A broad-based functional view is provided that is designed to more fully explore the balance between inflammo-toxic and inflammo-resolution factors that govern chronic disease progression...
  8. ncbi The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP
    Carol A Colton
    Division of Neurology, Duke University Medical Center, Durham, NC 27710, USA
    J Alzheimers Dis 15:571-87. 2008
    ..As APP/NOS2(-/-) bigenic mice more fully model the human AD disease pathology, they may serve as a tool to better understand disease progression in AD and the role of NO in altering chronic neurological disease processes...
  9. ncbi The usefulness and challenges of transgenic mouse models in the study of Alzheimer's disease
    Donna M Wilcock
    Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA
    CNS Neurol Disord Drug Targets 9:386-94. 2010
    ..It will also discuss the limitations associated with studying some of these mice and how transgenic mouse models have contributed to the development of therapeutics for the treatment of Alzheimer's disease...

Research Grants2

  1. Dysregulation of the neurovascular unit in Alzheimer's Disease.
    Donna Wilcock; Fiscal Year: 2007
    ..Overall, the studies to be performed in this research proposal will advance the understanding of the causes of microhemorrhage and the role of the neurovascular unit in Alzheimer's disease. ..